William Berger
Allergy · Mission Viejo, CANPI 1538260583
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.2%. Reporting peaked in 2019 at $41,548 and has fallen 99.3% since, to $286 in 2025. Among allergy clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $588.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$15K
- AstraZeneca$15K
- Optinose US, Inc.$10K
- Regeneron Healthcare Solutions, Inc.$8K
- Merck$5K
- Hikma Pharmaceuticals USA$5K
- plus $18K from 18 others
Across 249 payments — averaging $3615.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$230K
- Regeneron$192K
- Novartis$92K
- Incyte Corporation$90K
- AbbVie$72K
- Cipla USA Inc.$56K
- plus $168K from 8 others
What the payments were for
- Consulting fees$28,39737%
- Speaking & faculty fees$33,50444%
- Grants$4,8116%
- Travel & lodging$4,8566%
- Food & beverage$4,3886%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $15,309 |
| AstraZeneca | 27 | $14,626 |
| Optinose US, Inc. | 23 | $10,344 |
| Regeneron Healthcare Solutions, Inc. | 9 | $7,909 |
| Merck | 2 | $5,298 |
| Hikma Pharmaceuticals USA | 6 | $4,686 |
| Mylan Specialty L.p. | 1 | $3,750 |
| Sanofi | 4 | $3,173 |
| Mylan Inc. | 1 | $2,557 |
| Alk-abello, Inc | 10 | $2,179 |
| Teva Pharmaceuticals USA, Inc. | 6 | $1,856 |
| Boehringer Ingelheim | 5 | $1,702 |
| Mylan Pharmaceuticals Inc. | 1 | $675 |
| AbbVie | 1 | $575 |
| Eyevance Pharmaceuticals LLC | 1 | $500 |
| Pfizer | 6 | $321 |
| Genentech USA, Inc. | 2 | $205 |
| Circassia Inc. | 2 | $121 |
| Amgen | 2 | $41 |
| Kaleo, Inc. | 2 | $39 |
| CSL Behring | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| GSK | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$75,956 in reported general payments places this provider in the 95th percentile of 117 allergy providers in California.
Other allergy in Mission Viejo
- Geeta VenkatMission Viejo$5K
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- Sandra ChristiansenSan Diego$74K
- Stephen WongHacienda Heights$50K
- Michelle YasharpourBeverly Hills$48K
- Stuart EpsteinBeverly Hills$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.